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The hidden threat of hepatitis B
July 28 is World Hepatitis Day—a time to “join together to 
make the elimination of viral hepatitis our next greatest 
achievement”. Hepatitis is, belatedly, beginning to nudge 
its way into the global awareness. Having been neglected 
entirely in the Millennium Development Goals, it gets a 
name-check alongside AIDS, tuberculosis, and malaria 
within Sustainable Development Goal target 3.3, and—
at the World Health Assembly in May this year—the ﬁ rst 
Global Health Sector Strategy on Viral Hepatitis was 
endorsed. This much-anticipated strategy has a goal of 
eliminating viral hepatitis as a major public health threat 
by 2030, and particularly focuses on hepatitis B and C 
viruses, which cause the greatest burden worldwide. 
Hepatitis B virus (HBV) is responsible for half of all 
deaths globally from viral hepatitis, half of all deaths 
from liver cancer, and a third of all deaths from liver 
cirrhosis. Approximately 240 million people worldwide 
are chronically infected with the virus, mostly in east Asia 
and sub-Saharan Africa, where 5–10% of the population 
are thought to be carriers. In such regions, most people 
acquire the infection as infants via vertical transmission, 
and it is this route that is the most dangerous. Whereas 
the vast majority of individuals who acquire the disease 
as adults experience a brief illness and go on to clear the 
virus completely, those infected at birth rarely develop 
symptoms yet are unable to mount a suﬃ  cient immune 
response to destroy the virus. It therefore remains in 
the body, inactive but infectious, for decades. 20–30% 
will experience viral reactivation and a greatly increased 
risk of cirrhosis or liver cancer. Treatment of active 
disease with antiviral drugs aims only to suppress viral 
replication and prevent progression, and is thus a life-
long commitment. Ultimately, however, up to 40% of 
men and 15% of women with vertically acquired HBV 
infection will die of cirrhosis or liver cancer. 
Although a vaccine exists and its coverage globally 
averages 84%, it is not always protective in infants 
whose mothers have very high viral loads, and is of 
no comfort to the millions currently living with this 
insidious infection. Screening for carrier status and 
regular blood tests for those found positive are therefore 
crucial. Yet, as Maud Lemoine and colleagues explain in 
an Article in this month’s issue, routine screening in one 
of the highest burden regions—sub-Saharan Africa—
is rare. Lemoine and colleagues aimed to determine 
whether a community screening programme could be 
set up, engaged with, and successfully linked to care in 
The Gambia. Screening uptake was an encouraging 69% 
(5980 of 8170 adults), and 8% were found to be positive 
for hepatitis B surface antigen (HBsAg). None of those 
asked were aware of their status. Linkage to care at 
the tertiary referral centre was high (81%), but only 
4% were eligible for treatment, suggesting that such 
a programme is likely to be feasible and not a huge 
burden on the health budget. A companion Article by 
Shevanthi Nayagam and colleagues provides further 
reassurance about cost-eﬀ ectiveness.
In other news, a study published last month showed 
that tenofovir treatment for pregnant women 
with high viral loads could signiﬁ cantly reduce the 
chance of vertical transmission when combined with 
immunoglobulin prophylaxis and HBV vaccination 
of infants. WHO plans to update its recently released 
guidelines on the management of chronic hepatitis B 
infection to include these promising ﬁ ndings.
Tenofovir, then, is a key drug in both the prevention 
and treatment of chronic hepatitis B in resource-limited 
settings, yet doubts over its aﬀ ordability remain. 
Nayagam and colleagues’ costing analysis assumed a 
generic price of US$48 per person per year, yet currently 
only HIV programmes are eligible for this reduced price. 
Additionally, in many middle-income countries such as 
China, where the mother-to-child transmission study 
was done, tenofovir is not yet available in generic form: 
in China it costs a punishing $2920 per person per year.
WHO’s new strategy calls for 90% of people with 
chronic hepatitis B to know their status and for 
treatment coverage to reach 80% of eligible patients 
by 2030. One could be forgiven for feeling sceptical. 
But by emulating the HIV story, not least in terms of 
education, political lobbying, and determined action 
on drug and diagnostic costs, and by taking advantage 
of the extensive infrastructure and systems already set 
up for HIV screening, elimination ought not to be seen 
as utopian. Hepatitis B is a hidden threat both to public 
health and to patients themselves, but the tools exist 
to prevent and treat it. It’s time to put them to use. 
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